The top two enriched GSEA pathways in the decreased genes after RBM5 KO are associated with FLT3 inhibitors, including gilteritinib and TP0903 (Fig. 5d), suggesting that the FLT3 gene might contribute to AML survival after the loss of RBM5. The gene discussed is FLT3; the disease is acute myeloid leukemia.